埃索美拉唑联合莫沙必利与铝碳酸镁治疗难治性胃食管反流病的临床疗效

Clinical effect of esomeprazole combined with mosapride and hydrotalcite in treating refractory gastroesophageal reflux disease

目的探讨埃索美拉唑联合莫沙必利、铝碳酸镁治疗难治性胃食管反流病(RGERD)的临床疗效。方法选取彭州市中西医结合医院内科2014年7月—2017年7月收治的RGERD患者62例,随机分为A组30例与B组32例。A组患者采用埃索美拉、枸橼酸莫沙比利治疗,B组患者在A组基础上给予铝碳酸镁治疗,两组患者均持续治疗8周。比较两组患者治疗前及治疗4、8周后发作频率及症状严重程度评分、临床疗效,观察患者治疗期间药物不良反应发生情况。结果治疗前,两组患者发作频率及症状严重程度评分比较,差异无统计学意义(P>0.05);治疗4、8周后,B组患者发作频率及症状严重程度评分低于A组(P<0.05)。B组患者临床疗效优于A组(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论采用埃索美拉唑联合莫沙必利与铝碳酸镁治疗RGERD的临床疗效确切,可有效改善患者的临床症状,减轻疾病严重程度,且安全性较高。

Objective To investigate the clinical effect of esomeprazole combined with mosapride and hydrotalcite in treating refractory gastroesophageal reflux disease （ RGERD ） .Methods A total of 62 cases of RGERD patients were selected from July 2014 to July 2017 in Pengzhou Traditional Chinese and Western Medicine Hospital, which were randomly divided into A group （ n=30 ） and B group （ n=32 ） .A group was treated with esomeprazole combined with mosapride, B group was given hydrotalcite based on A group.The scores of attack frequency and severity of symptoms before treatment and after treatment of 4, 8 weeks, clinical effect were compared between the two groups, and the incidence of adverse reactions were observed.Results Before treatment, no significant differences of scores of attack frequency or scores of severity of symptoms was found between the two groups （ P〉0.05 ） ; after treatment of 4, 8 weeks, the scores of attack frequency and severity of symptoms of B group were lower than A group （ P〈0.05 ） .The B group of clinical effect was better than A group （ P〈0.05 ） .There was no significant difference of the incidence rate of adverse reactions between the two groups （ P〉0.05 ） .Conclusion Esomeprazole combined with mosapride and hydrotalcite have an exactly clinical effect in treating RGERD, it can effectively improve the clinical symptoms, reduce the severity of symptoms, and with high safety.